CS MEDICA Update: Rescheduled Q4 2023 Presentation

CS MEDICA announces a new date for the Q4 2023 Report Presentation event: 12 April at 11 AM CET.

CS MEDICA announces a new date for our live-streamed event covering highlights from the Q4 2023 Report: 12 April at 11 AM CET. We invite all stakeholders to join us for the live-streamed event. Please register and submit questions prior to the live presentation or/and vote for the best questions at the following link >>

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients' needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags: